EE79 Budget and Time Impact Analysis of Introducing Subcutaneous Pembrolizumab to Patients From Institution HCP and Patient Perspectives in the United States (US)
Abstract
Authors
Ying Xiao Sabine Oskar Spencer Notinger Colin Burke Karl Patterson Jingshu Wang